Lainate, Italy – 29 May 2020 – Cassiopea S.p.A. (SIX: SKIN), a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, today announced the results of the extraordinary shareholders meeting held on 28 May 2020 in Lainate.
Owing to the COVID-19 health emergency and in compliance with art. 106 of Law-Decree n. 18 dated March 17, 2020 aimed at minimizing travel and gatherings, attending and voting at the shareholders meeting could only occur through the granting of a specific proxy to the designated representative (Dario Trevisan, lawyer).
5,593,102 shareholder votes were represented at the extraordinary shareholders meeting. This represents 55.93% of all votes.
5,593,102 shareholder votes representing 100% of the total votes cast voted for the increase of the share capital by EUR 750 thousand reserved to existing shareholders
265,670 shareholder votes representing 4.75% of the total votes cast voted for the increase of the share capital by EUR 750 thousand without rights to existing shareholders.
5,504,067 shareholder votes representing 98.41% of the total votes cast voted to cancel the Board of Directors existing authorization to issue up to 500,000 shares for the benefit of the employee stock option plan and to delegate to the Board of Directors the faculty to increase the Company’s capital by issuing up to 900,000 shares for the benefit of the employee stock option plan.
Cassiopea is a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia and genital warts. Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. Cassiopea plans to determine the most efficient way to effectively commercialize the products in the U.S. after the planned approval of Clascoterone Cream 1% and to partner the products for countries outside of the US. For further information on Cassiopea, please visit www.cassiopea.com.
|Half Year Report 2020||July 2020|
|Investora||23-24 September 2020, Zurich|
|Credit Suisse Small & Mid Cap Conference||18-20 November 2020, Zurich|
|Jefferies Global Health Care Conference||19-21 November 2020, London|
Dr. Chris Tanner, CFO and Head of Investor Relations
Tel: +39 02 868 91 124
Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cassiopea has no obligation to publicly update or revise any forward-looking statements.